GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

GSK (GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. Read more here.

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

GSK’s Jemperli (dostarlimab) has been granted expanded approval by the European Commission (EC) to treat a broader range of endometrial cancer patients. The PD-1-blocking antibody has been authorised ...

(Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, ...

(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...